期刊文献+

肠溶淀粉空心胶囊对奥美拉唑的相容性研究

Compatibility Study of Enteric Starch Hollow Capsules to Omeprazole
下载PDF
导出
摘要 将奥美拉唑胶囊剂分别置于高温(40℃)、高湿RH(75±5%)、强光(4500±500Lx)条件下5d和10d,按《中国药典》方法测定奥美拉唑胶囊剂的外观性状、溶出度、药物含量和有关物质。结果发现胶囊剂外观、色泽等性状均无明显变化,含量测定值在93~99%,变化均小于5%。在模拟胃液中,2h后胶囊外观形态完整;在模拟肠液中,药物溶出度在93~101%。由此表明,肠溶淀粉空心胶囊与奥美拉唑相容性良好。 The omeprazole capsules samples were placed in conditions of temperature of 40℃,relative humidity of(75±5)%and strong light of(4500±500)Lx for 5d and 10d,respectively.Properties,dissolution,content of omeprazole capsules were used as indicators,according to the method of Chinese Pharmacopoeia.The results showed that there were no obvious differences for appearance of capsules before and after the experiment.The contents of omeprazole enteric capsules were 93%~99%,and the contents change were less than 5%.In the simulated gastric juice,the appearance of the capsules was complete;And the dissolution of omeprazole in the simulated intestinal fluid was 93~101%.Therefore,there exists good compatibility between omeprazole and enteric starch hollow capsules.
作者 程丹 王叶青 CHENG Dan;WANG Ye-qing(Zhejiang Wanli University,Ningbo Zhejiang 315100)
机构地区 浙江万里学院
出处 《浙江万里学院学报》 2018年第1期83-87,共5页 Journal of Zhejiang Wanli University
基金 浙江省"生物工程"重中之重学科学生创新计划项目资助项目(CX2016004)
关键词 肠溶淀粉空心胶囊 奥美拉唑 相容性 enteric starch hollow capsule omeprazole compatibility
  • 相关文献

参考文献2

二级参考文献19

  • 1张夕瑶,王永禄,王栋,李学明.HPMC胶囊的体内外研究现状与应用展望[J].中国生化药物杂志,2014,34(1):138-141. 被引量:5
  • 2蒋新国,王孝俊,朱芳海,李正伟,奚念朱.海藻酸钠的分子量与缓释作用[J].药学学报,1994,29(4):306-310. 被引量:18
  • 3Shun-jiang XU,Wei-juan GAO,Bin CONG,Chun-ling MA,Shu-jin LI,Yi-ling LING,Zhen-yong GU,Yu-xia YAO.Effect of cholecystokinin octapeptide on diacylglyceroI-PKC signaling pathway in rat pulmonary interstitial macrophages stimulated by lipopolysaccharide[J].Acta Pharmacologica Sinica,2005,26(12):1497-1504. 被引量:6
  • 4ANGIOLILLO D J , GIBSON C M , CHENG S , et al. Differentialeffects of omeprazole and pantoprazole on the pharmacodynamicsand pharmacokinetics of clopidogrel inhealthy subjects:randomized, placebo - controlled,crossovercomparison studies[J] . Clin Pharmacol Ther, 2 0 1 1 ,8 9 ( 1 ) : 6 5 -74.
  • 5SUNG J J,LUO D,WU J C,et al. Early clinical experienceof the safety and effectiveness of Hemospray in achievinghemostasis in patients with acute peptic ulcerbleeding[J] . Endoscopy,2011 ,43(4) :291 -295.
  • 6CHENG E,ZHANG X,HUO X ,t al. Omeprazole blockseotaxin - 3 expression by oesophageal squamous cells from patients with eosinophilic oesophagitis and GORD [J].Gut,2 0 1 3 , 6 2 ( 6 ) :824 -832.
  • 7TOMS - WHITTLE L M, JOHN L H, BUCKLEY D A.Drug - induced subacute cutaneous lupus erythematosusasociated with omeprazole[J]. Clin Exp Dermatol,2011,3 6 (3) :281 -283.
  • 8BOWEN C L , HEMBERGER M D, KEHLER J R, et al.Utility of dried blood spot sampling and storage for increasedstability of photosensitive compounds [J]. Bioanalysis, 0 1 0 , ( 11 ) : 1823 -1828.
  • 9FONT ANAP,BERDAGUEP, CASTELLI C,et al. Clinicalpredictors of dual aspirin and clopidogrel poor responsivenessin stable cardiovascular patients from the ADRIEstudy[J]. J Thromb Haemost,2010,8( 12) ;2614 -2623.
  • 10VYAS S, PATEL A, LADVA K D, et a . Development a dvalidation of a stability indicating method for the enantioselectiveestimation of omeprazole enantiomers in the enteric -coated formulations by high - performance liquid chromatogrnphy[J].J Pham Bioallied Sci,2011,3 (2) :310 -314.

共引文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部